The Effects of Nimotuzumab Alone and in Combination with Chemotherapy on Pulmonary Adenocarcinoma

SONG Hai-zhu,YI Jun,HUANG Gui-chun,SHI Yi
DOI: https://doi.org/10.3969/j.issn.1008-8199.2011.02.009
2011-01-01
Abstract:Objective Monoclone antibody targeted to epidermal growth factor receptor(EGFR) was proved to enhance the chemosensitivity of pulmonary adenocarcinoma.Nimotuzumab is a humanized monoclonal antibody that recognizes the human EGFR.This study was to investigate the effects of Nimotuzumab alone and in combination with chemotherapy on human pulmonary adenocarcinoma cell lines with different levels of EGFR overexpression and mutations of EGFR,KRAS and PI3KCA.Methods The EGFR status of three cell lines A549,SPC-A1 and SPC-A1/DTX were detected by immunohistochemistry.PCR sequencing and a mutant-enriched liquidchip were used in detection of EGFR,KRAS and PI3KCA mutations.We then evaluated nimotuzumab effects on growth,cell cycle distribution and complement-dependent cytotoxicity(CDC).These cancer cell lines were treated with nimotuzumab alone or in combination with chemotherapy in vitro to determine the cooperative effects.Results The status of EGFR:A549(-),SPC-A1(+),SPC-A1/DTX(3 +).A549 with KRAS/Codon13 and PI3KCA/E9,E20 mutations.SPC-A1 with no mutation,and SPC-A1/DTX with PI3KCA/E20 mutation.A obvious shift into the G0/G1 phase of the cell cycle and CDC effects were revealed in EGFR-expressing cell lines after 24 hours of nimotuzumab treatment.Cooperative growth inhibitory effects were observed in EGFR-expressing cell lines both in chemotherapy with cisplatin or docetaxel.Conclusion Nimotuzumab alone couldn′t inhibit the growth of A549 and has no cooperative growth inhibitory with chemotherapy.The cooperative growth inhibitory effects of nimotuzumab and chemotherapy depended more on the expression of EGFR than the mutations of EGFR,KRAS or PI3KCA.Proper patient selection will be critical to the success of nimotuzumab.
What problem does this paper attempt to address?